Efficacy and safety of vinorelbine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma patients

被引：1

作者：

Barth, Claire ^{[1
]}

Naveau, Louise ^{[1
]}

Touboul, Emmanuel ^{[1
]}

Perie, Sophie ^{[2
]}

Bamogho, Edith ^{[1
]}

Haberer-Guillerm, Sophie ^{[1
]}

Schlienger, Michel ^{[1
]}

St Guily, Jean Lacau ^{[2
]}

Huguet, Florence ^{[1
]}

机构：

[1] Univ Paris 06, Tenon Hosp, HUEP, Dept Radiat Oncol, Paris, France

[2] Univ Paris 06, Tenon Hosp, HUEP, Dept Head & Neck Surg, Paris, France

来源：

ANTI-CANCER DRUGS | 2016年 / 27卷 / 04期

关键词：

vinorelbine; head and neck cancer; chemotherapy; recurrent; metastatic; PLATINUM-BASED CHEMOTHERAPY; PHASE-II TRIAL; METASTATIC HEAD; RECURRENT; CANCER; CARBOPLATIN; PACLITAXEL; CISPLATIN; CETUXIMAB; METHOTREXATE;

D O I：

10.1097/CAD.0000000000000333

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this study was to evaluate the efficacy and tolerance of vinorelbine as a single agent in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Patients were treated with oral or intravenous vinorelbine according to the pluridisciplinary tumor board's decision. Efficacy and safety outcomes were analyzed retrospectively. Twenty-three patients were included in the study. Sixteen patients (69%) had received at least two previous lines of chemotherapy. The disease control rate was 19%. The median progression-free survival was 2.6 months and the median overall survival was 3.4 months. The rate of grade 3-4 side effects was low (13%). Only one patient discontinued treatment because of side effects. Vinorelbine seems to be a well-tolerated regimen in heavily pretreated patients. However, this regimen does not seem to be efficient enough to be recommended.

引用

页码：349 / 352

页数：4

共 50 条

[31] Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma [J].

Weiss, Jared M. ;

Bagley, Stephen ;

Hwang, Wei-Ting ;

Bauml, Joshua ;

Olson, Juneko Grilley ;

Cohen, Roger B. ;

Hayes, David Neil ;

Langer, Corey .

CANCER, 2016, 122 (15) :2350-2355

[32] Established treatment concepts for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSSC) [J].

Kloppenburg, Marcel ;

Mildner, Finn ;

Kasseroler, Maria Theresia ;

Dejaco, Daniel ;

Amann, Arno .

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (04) :395-399

[33] Efficacy and Safety of Paclitaxel Combined With Cetuximab for Head and Neck Squamous Cell Carcinoma [J].

Okada, Takuro ;

Okamoto, Isaku ;

Sato, Hiroki ;

Ito, Tatsuya ;

Miyake, Keitaro ;

Tsukahara, Kiyoaki .

IN VIVO, 2021, 35 (02) :1253-1259

[34] Allergy History and Immunotherapy Response in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [J].

Alkhatib, Hosam H. ;

Maroun, Christopher A. ;

Guller, Meytal ;

Cooper, Dylan J. ;

Wu, Evan S. ;

Eisele, David W. ;

Fakhry, Carole ;

Pardoll, Drew ;

Seiwert, Tanguy Y. ;

Zhu, Gangcai ;

Mandal, Rajarsi .

OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2024, 170 (03) :828-836

[35] Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME [J].

Chevalier, Thomas ;

Daste, Amaury ;

Saada-Bouzid, Esmaa ;

Loundou, Anderson ;

Peyraud, Florent ;

Lambert, Tiphaine ;

Le Tourneau, Christophe ;

Peyrade, Frederic ;

Dupuis, Charlotte ;

Alfonsi, Marc ;

Fayette, Jerome ;

Reure, Juliette ;

Huguet, Florence ;

Fakhry, Nicolas ;

Toullec, Clemence ;

Salas, Sebastien .

CANCER MEDICINE, 2021, 10 (12) :3952-3963

[36] Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [J].

Aggarwal, Charu ;

Saba, Nabil F. ;

Algazi, Alain ;

Sukari, Ammar ;

Seiwert, Tanguy Y. ;

Haigentz, Missak ;

Porosnicu, Mercedes ;

Bonomi, Marcelo ;

Boyer, Jean ;

Esser, Mark T. ;

Cheng, Lily I. ;

Agrawal, Sonia ;

Jennings, Emily C. ;

Durham, Nicholas M. ;

Fraser, Karl ;

Lissa, Delphine ;

Gong, Maozhen ;

Ceaicovscaia, Natalia ;

Hernandez, Amaya Gasco ;

Kumar, Rakesh .

CLINICAL CANCER RESEARCH, 2023, 29 (03) :560-570

[37] Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population [J].

Chen, Wen-Chun ;

Chu, Pen-Yuan ;

Lee, Yu-Ting ;

Lu, Wen-Bin ;

Liu, Chun-Yu ;

Chang, Peter Mu-Hsin ;

Yang, Muh-Hwa .

MEDICINE, 2017, 96 (52)

[38] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck [J].

Hitt, R. ;

Irigoyen, A. ;

Cortes-Funes, H. ;

Grau, J. J. ;

Garcia-Saenz, J. A. ;

Cruz-Hernandez, J. J. .

ANNALS OF ONCOLOGY, 2012, 23 (04) :1016-1022

[39] Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK [J].

Uozumi, Shinya ;

Enokida, Tomohiro ;

Suzuki, Shinya ;

Nishizawa, Aya ;

Kamata, Hayato ;

Okano, Tomoka ;

Fujisawa, Takao ;

Ueda, Yuri ;

Okano, Susumu ;

Tahara, Makoto ;

Yamaguchi, Masakazu .

FRONTIERS IN ONCOLOGY, 2018, 8

[40] Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis [J].

Yu, Xiao ;

Su, Xiaolei ;

Fang, Ling ;

Zhang, Honglei ;

Chen, Xi ;

Pu, Yu ;

Liu, Hongyi ;

Guo, Rui .

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (03) :1391-1401

← 1 2 3 4 5 →